GlassScriptPhysician profile
Sarah E Espinoza
NPI 1396366605
$5,853.48
in general payments reported to CMS, 2019-2025
26 companies · $1,706 in 2025
The $1,706 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.88 · 2022: $922 · 2023: $1,580 · 2024: $1,627 · 2025: $1,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,913.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,110.28 | 2022-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $1,042.04 | 2022-2025 | |
| Axsome Therapeutics, INC. | $595.18 | 2023-2025 | Sunosi, Auvelity |
| Otsuka America Pharmaceutical, INC. | $393.32 | 2022-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $360.00 | 2023-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $319.29 | 2022-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $294.29 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $294.09 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $284.17 | 2022-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $252.62 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $163.51 | 2022-2024 | Trintellix |
| Alkermes, INC. | $139.09 | 2022-2025 | Lybalvi, Vivitrol |
| Abbott Laboratories | $108.49 | 2025 | Freestyle Libre 3 |
| Bausch Health US, LLC | $101.31 | 2022-2024 | Aplenzin |
| Tris Pharma INC | $79.81 | 2024-2025 | Dyanavel Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $79.24 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $52.39 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $49.00 | 2023 | Quviviq |
| Corium, LLC | $21.98 | 2023 | Azstarys |
| Pear Therapeutics (US), INC. | $20.82 | 2022 | |
| Tempus Ai, INC | $18.54 | 2025 | Xt Cdx |
| Biogen, INC. | $17.88 | 2021 | |
| Jazz Pharmaceuticals INC. | $16.02 | 2022 | |
| Inspire Medical Systems, INC. | $14.07 | 2025 | Inspire |
| E.R. Squibb & Sons, L.L.C. | $13.55 | 2024 | |
| Acadia Pharmaceuticals INC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.